Mirum Pharmaceuticals Inc
NASDAQ:MIRM
Intrinsic Value
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. [ Read More ]
The intrinsic value of one
MIRM
stock under the Base Case scenario is
52.42
USD.
Compared to the current market price of 24.49 USD,
Mirum Pharmaceuticals Inc
is
Undervalued by 53%.
MIRM could be a value trap.A value trap occurs when a stock looks inexpensive based on fundamental analysis but fails to reach its intrinsic valuation over time, often due to underlying issues not reflected in quantitative data.
Scrutinize beyond numbers; assess long-term potential.
Mirum Pharmaceuticals Inc's market capitalization is 1.1B USD.
MIRM stock price is 24.49 USD.
MIRM stock price (24.49 USD) is 53% less than its Intrinsic Value (52.42 USD).
MIRM stock price (24.49 USD) is 71% less than its Relative Value (83.91 USD). Open Relative Valuation
MIRM has upside potential of 104% compared to the average analyst price target.
Open Wall St Estimates
MIRM's D/E (Debt to Equity) is equal to 1.23.
MIRM's ROE (Return on Equity) has increased in the last 3 years from -91% to -84%, and is approaching profitability.
MIRM has positive Net Debt. This means that the company has more debt (306m USD) than cash and short-term investments (286m USD).
MIRM's long-term assets (647m USD) exceed its long-term liabilties (398m USD).
MIRM's Revenue has grown by an exceptional 142% over the past 12 months.
MIRM's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -1 939% to -40%, and is approaching profitability.
MIRM's Revenue is forecast to grow at a rate of 43% per year over the next 3 years.
MIRM has negative Operating Income for the last twelve months.
MIRM has negative Net Income for the last twelve months.
MIRM's ROE (Return on Equity) for the past 12 months is negative and is equal to -84%.
MIRM's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -40%.
MIRM has positive Gross Profit for the last twelve months.
MIRM has negative Free Cash Flow for the last twelve months.
MIRM has negative three-year average ROE (Return on Equity): -96%. The company is not efficient at transforming stockholders' equity into net income.
MIRM has negative three-year average ROIC (Return on Invested Capital): -414%. The company is not efficient at using invested capital to generate operating income.
MIRM's short-term assets (388m USD) exceed its short-term liabilties (87m USD).
MIRM's Altman Z-Score is very low and is equal to 0.63.
MIRM doesn't generate enough operating income (-109m USD) to safely cover interest payments on its debt (7m USD).
Valuation Backtest
Mirum Pharmaceuticals Inc
Run backtest to discover the historical profit from buying and selling
MIRM
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Mirum Pharmaceuticals Inc
Balance Sheet Decomposition
Mirum Pharmaceuticals Inc
| Current Assets | 387.5m |
| Cash & Short-Term Investments | 286.3m |
| Receivables | 68m |
| Other Current Assets | 33.2m |
| Non-Current Assets | 259.1m |
| PP&E | 2m |
| Intangibles | 252.9m |
| Other Non-Current Assets | 4.2m |
| Current Liabilities | 87.1m |
| Accounts Payable | 7.4m |
| Accrued Liabilities | 79.6m |
| Non-Current Liabilities | 310.9m |
| Long-Term Debt | 306.4m |
| Other Non-Current Liabilities | 4.5m |
Earnings Waterfall
Mirum Pharmaceuticals Inc
|
Revenue
|
186.4m
USD
|
|
Cost of Revenue
|
-47m
USD
|
|
Gross Profit
|
139.3m
USD
|
|
Operating Expenses
|
-248.5m
USD
|
|
Operating Income
|
-109.2m
USD
|
|
Other Expenses
|
-54.3m
USD
|
|
Net Income
|
-163.4m
USD
|
Free Cash Flow Analysis
Mirum Pharmaceuticals Inc
MIRM Profitability Score
Profitability Due Diligence
Mirum Pharmaceuticals Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
Score
Mirum Pharmaceuticals Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
MIRM Solvency Score
Solvency Due Diligence
Mirum Pharmaceuticals Inc's solvency score is 40/100. The higher the solvency score, the more solvent the company is.
Score
Mirum Pharmaceuticals Inc's solvency score is 40/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MIRM Price Targets Summary
Mirum Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
MIRM
is 49.98 USD
with a low forecast of 33.33 USD and a high forecast of 75.6 USD.
Ownership
MIRM Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
MIRM Price
Mirum Pharmaceuticals Inc
| Average Annual Return | 16.09% |
| Standard Deviation of Annual Returns | 46.03% |
| Max Drawdown | -54% |
| Market Capitalization | 1.1B USD |
| Shares Outstanding | 47 003 300 |
| Percentage of Shares Shorted | 19.06% |
Company Profile
Mirum Pharmaceuticals Inc
Country
Industry
Market Cap
Dividend Yield
Description
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Foster City, California and currently employs 137 full-time employees. The company went IPO on 2019-07-18. The firm is focused on the identification, acquisition, development, and commercialization of therapies for rare and orphan diseases. The firm's main focus is the development and commercialization of LIVMARLI (maralixibat) oral solution (Livmarli) and Volixibat. Its pipeline consists of rare pediatric indications for Livmarli and orphan adult indications for its second product candidate, Volixibat. Livmarli is an oral solution as a once-daily medicine for cholestatic pruritus in patients with Alagille syndrome (ALGS) one year of age and older. Volixibat, is an oral, minimally absorbed agent designed to inhibit ileal bile acid transporter (IBAT), for the treatment of adult patients with cholestatic liver diseases. The firm is developing volixibat for the treatment of intrahepatic cholestasis of pregnancy (ICP), primary sclerosing cholangitis (PSC), and primary biliary cholangitis (PBC).
Contact
IPO
Employees
Officers
The intrinsic value of one
MIRM
stock under the Base Case scenario is
52.42
USD.
Compared to the current market price of 24.49 USD,
Mirum Pharmaceuticals Inc
is
Undervalued by 53%.
You don't have any saved screeners yet
